Health Care & Life Sciences » Biotechnology | Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
1.10
18.80
35.80
37.80
71
Gross Income
-
1.10
18.80
35.80
37.80
71
SG&A Expense
3,676.40
7,269.50
11,970.30
18,660.20
22,450.50
39,628.10
EBIT
3,676.40
7,270.60
11,989.10
18,696.00
22,488.40
39,699.20
Unusual Expense
16,896.20
2,327.50
-
-
-
-
Interest Expense
159.30
244.20
112.30
105.50
113.50
146.80
Pretax Income
13,060.50
5,187.30
12,090.30
18,699.50
22,340.60
38,893.20
Consolidated Net Income
12,237.90
5,187.30
12,090.30
18,699.50
22,340.60
38,893.20
Net Income
12,237.90
5,187.30
12,090.30
18,699.50
22,340.60
38,893.20
Net Income After Extraordinaries
12,237.90
5,187.30
12,090.30
18,699.50
22,340.60
38,893.20
Net Income Available to Common
1,109.90
9,573.90
12,090.30
18,699.50
22,340.60
38,893.20
EPS (Basic)
17.58
2.49
1.40
1.65
1.40
1.79
Basic Shares Outstanding
4,035.20
3,818.20
8,633.90
11,352.20
15,921.90
21,685.60
EPS (Diluted)
3.33
2.49
1.40
1.65
1.40
1.79
Diluted Shares Outstanding
4,521.30
3,850.60
8,633.90
11,352.20
15,921.90
21,685.60
EBITDA
3,676.40
7,269.50
11,970.30
18,660.20
22,450.50
39,628.20
Non-Operating Interest Income
0.00
0.00
11.10
102.00
261.30
952.70
Other After Tax Income (Expense)
822.60
-
-
-
-
-
Preferred Dividends
11,128.00
4,386.70
-
-
-
-

About Aldeyra Therapeutics

View Profile
Address
131 Hartwell Avenue
Lexington Massachusetts 02421
United States
Employees -
Website http://www.aldeyra.com
Updated 07/08/2019
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.